Topical application of an mTOR inhibitor suppresses mast cells in a murine skin: A novel option for cutaneous mastocytosis

The skin is home to a vast network of immune sentinels called mast cells. Under normal circumstances, these cells stand guard, ready to release chemicals that help the body fight off invaders or heal a wound. However, in a condition known as cutaneous mastocytosis, these cells multiply uncontrollably and cluster together in the skin. This creates persistent, often itchy, brownish patches that can flare up when scratched. While these lesions sometimes fade as children grow older, they often remain into adulthood, causing cosmetic concerns and, in some cases, triggering severe allergic reactions. Currently, doctors have few options for treating these skin spots directly. Systemic medicines that travel through the whole body can work, but they carry risks of side effects that are too heavy for a condition limited to the skin. Researchers have long suspected that a specific internal signaling pathway, which acts like a switch telling cells to grow and divide, is stuck in the "on" position in these disease-causing cells. If a treatment could turn that switch off right where the skin lesions are, it might offer a safer, more targeted way to clear the rash without harming the rest of the body.

A team of researchers at Tokyo Medical University set out to test whether a drug called rapamycin, which is known to block that growth signal, could work when applied directly to the skin. They began by studying human mast cells grown in a laboratory dish. These cells came from two slightly different versions of a cell line, one carrying a specific genetic change and the other not. The scientists added rapamycin to the dishes and watched what happened over several days. They found that the drug did not kill the cells outright. Instead, it acted like a pause button, stopping the cells from dividing and growing. The cells remained alive but stopped multiplying, effectively freezing the expansion of the cluster. When the researchers looked at the molecular machinery inside the cells, they saw that the drug successfully blocked the chemical signals that usually tell the cells to grow. This effect was particularly strong in the cells carrying the specific genetic change, though it still worked on the others.

To see if this would work in a living body, the researchers turned to a mouse model. They injected human mast cells under the skin of mice that had immune systems designed not to reject human tissue. This allowed the human cells to grow into small tumors, mimicking the skin lesions seen in patients. Once the tumors were visible, the team began a daily treatment regimen. They applied a gel containing the drug to the skin over the tumors on one side of the mouse's back, while applying a plain gel without the drug to the other side as a control. Over the course of five weeks, the difference became striking. The tumors on the untreated side grew large and obvious. In contrast, the tumors on the treated side showed a marked difference depending on the cell type: while tumors made of cells with the specific genetic mutation became so small they could no longer be seen with the naked eye, tumors made of cells without that mutation continued to increase in size, though they were significantly smaller than the untreated controls. When the researchers examined the treated tissue under a microscope, they confirmed that the drug had successfully blocked the growth signals inside the cells and stopped them from dividing, just as it had in the lab dishes, although some residual proliferation remained in the non-mutated cells.

The study also looked at skin samples taken from human patients with the condition to see if the same biological signals were active in real people. They found that the growth signals were indeed turned on in the mast cells found in the skin lesions, and these cells were actively dividing. The cells with the specific genetic mutation showed the highest level of activity, suggesting they would be the most responsive to the treatment. The researchers concluded that applying the drug directly to the skin is a viable way to suppress the growth of these abnormal cells. While the study did not prove that the drug would cure the disease in humans, it provided strong evidence that a topical treatment could control the local proliferation of mast cells without the need for systemic medication. This approach offers a promising new direction for managing a condition that has long lacked effective local therapies, potentially turning a difficult-to-treat skin problem into one that can be managed with a simple daily application.